CLINICAL TRIALS PROFILE FOR ZEPATIER

All Clinical Trials for ZEPATIER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02743897 ↗	Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients	Active, not recruiting	Merck Sharp & Dohme Corp.	Phase 1/Phase 2	2016-05-01	This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation.
NCT02743897 ↗	Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients	Active, not recruiting	University of Pennsylvania	Phase 1/Phase 2	2016-05-01	This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation.
NCT02781649 ↗	Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients	Completed	Merck Sharp & Dohme Corp.	Phase 4	2016-07-20	In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant.
NCT02781649 ↗	Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients	Completed	Johns Hopkins University	Phase 4	2016-07-20	In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant.
NCT02786537 ↗	Study of Oral Treatments for Hepatitis C	Completed	AbbVie	Phase 4	2016-06-01	Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.
NCT02786537 ↗	Study of Oral Treatments for Hepatitis C	Completed	Merck Sharp & Dohme Corp.	Phase 4	2016-06-01	Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.

Clinical Trial Conditions for ZEPATIER

Condition Name

Condition Name for ZEPATIER
Intervention	Trials
Hepatitis C	13
Hepatitis C, Chronic	3
Chronic Hepatitis c	2
Refractory Liver Carcinoma	1

Condition MeSH

Condition MeSH for ZEPATIER
Intervention	Trials
Hepatitis C	24
Hepatitis	20
Hepatitis A	10
Hepatitis C, Chronic	6

Clinical Trial Locations for ZEPATIER

Trials by Country

Trials by Country for ZEPATIER
Location	Trials
United States	35
United Kingdom	3
Taiwan	3
Spain	1
Saudi Arabia	1

Trials by US State

Trials by US State for ZEPATIER
Location	Trials
Pennsylvania	5
Massachusetts	4
Maryland	3
Texas	3
Indiana	1

Clinical Trial Progress for ZEPATIER

Clinical Trial Phase

Clinical Trial Phase for ZEPATIER
Clinical Trial Phase	Trials
Phase 4	16
Phase 3	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for ZEPATIER
Clinical Trial Phase	Trials
Completed	12
Terminated	4
Active, not recruiting	4

Clinical Trial Sponsors for ZEPATIER

Sponsor Name

Sponsor Name for ZEPATIER
Sponsor	Trials
Merck Sharp & Dohme Corp.	16
University of Pennsylvania	4
Massachusetts General Hospital	2

Sponsor Type

Sponsor Type for ZEPATIER
Sponsor	Trials
Other	29
Industry	18
U.S. Fed	1

ZEPATIER Market Analysis and Financial Projection

Last updated: February 10, 2026

Clinical Trials Update for Zepatier

Zepatier (elbasvir/grazoprevir) was approved by the U.S. FDA in November 2016 for treating hepatitis C virus (HCV) genotypes 1 and 4. Since approval, clinical studies have focused on expanding efficacy data and optimizing patient outcomes. Key recent trials include:

• Real-world effect studies: Conducted across various populations, including HIV co-infected patients, demonstrating sustained virologic response (SVR) rates exceeding 90%. Ongoing post-market surveillance confirms safety and tolerability.

• Pediatric trials: Initiated to evaluate safety and efficacy in adolescents aged 12-17, with preliminary data indicating comparable SVR rates to adults.

• Combination therapies: Trials assessing Zepatier in combination with other antivirals to widen treatment options, especially for resistant strains. Data show promising SVR improvements but remain in early-phase development.

Market Landscape and Competitive Position

Zepatier faces competition primarily from other direct-acting antivirals (DAAs) approved for HCV. Major competitors include Harvoni (ledipasvir/sofosbuvir) from Gilead Sciences and Epclusa (sofosbuvir/velpatasvir), also from Gilead.

Market Share and Sales Analysis

• Sales figures: In 2022, Zepatier generated approximately $180 million globally, declining from peaks of $390 million in 2017. The decline correlates with increased competition and generic entry in some markets.

• Market penetration: Predominantly used in the U.S. and select European markets. Limited deployment in emerging markets due to patent restrictions and price sensitivity.

• Pricing and reimbursement: Average wholesale price (AWP) in the U.S. exceeds $40,000 for a 12-week course. Reimbursement policies favor front-line therapies with higher SVR rates, pressuring Zepatier's market share.

Regulatory Status and Pipeline Developments

• Label updates: The FDA approved labels to include data for ESRD patients on dialysis, improving the drug's applicability.

• Future pipeline: No current pipeline for Zepatier-specific formulations. Bayer, which markets Zepatier, explores combination regimens with newer agents for resistant HCV strains.

Market Projection and Growth Outlook

The global HCV treatment market is projected to grow modestly, driven by increased screening programs and new drug development. The compound annual growth rate (CAGR) from 2023 to 2028 is estimated at 2-3%.

Factors Influencing Growth

• Generic competition: Multiple generics in the U.S. and Europe limit Zepatier's market share. Patent expirations in key territories by 2024 could erode pricing power.

• Treatment paradigm shifts: The focus shifts to pan-genotypic regimens that simplify treatment algorithms, favoring drugs like Epclusa and Mavyret over genotype-specific options like Zepatier.

• Regulatory and policy initiatives: Increased screening efforts and access programs improve market potential, especially in underserved populations.

Regional Market Projections

Region	2023 Market Value (USD million)	2028 Projection (USD million)	CAGR (%)
North America	300	330	2.5
Europe	180	210	3.0
Asia-Pacific	100	140	6.0
Rest of World	70	80	2.0

The Asia-Pacific region exhibits the highest growth potential, owing to expanding healthcare infrastructure and diagnosis rates.

Key Takeaways

• Clinical trials confirm Zepatier's efficacy and safety in various populations, including co-infected and pediatric groups.
• Market sales are declining due to drug competition, patent expirations, and shift toward pan-genotypic therapies.
• The therapy's future depends on strategies to differentiate through combination regimens, expanded indications, or price adjustments.
• The global HCV market remains steady but challenges due to generics and evolving treatment protocols.
• Growth prospects are stronger in emerging markets, where screening and access initiatives are expanding.

FAQs

1. What are the primary indications for Zepatier?
Zepatier is approved for treating chronic HCV genotypes 1 and 4 in adults, including those with or without cirrhosis and in specific patient populations like HIV co-infection.

2. Has Zepatier received any recent regulatory updates?
Yes, the FDA expanded labeling to include efficacy data for patients with end-stage renal disease on dialysis.

3. How does Zepatier compare to other HCV treatments?
While effective, Zepatier's market share is decreasing relative to pan-genotypic agents like Epclusa, which simplify treatment protocols and are increasingly favored.

4. What is the outlook for Zepatier in emerging markets?
Limited data exist, but expanding screening and reduced pricing could improve uptake. Patent expiry may enhance generic availability.

5. Are there ongoing trials to enhance Zepatier’s efficacy?
Current efforts focus on combinations with new antivirals for resistant genotypes, but no major late-stage trials are announced for Zepatier alone.

---

References

1. Food and Drug Administration (FDA). Zepatier (elbasvir/grazoprevir) approval announcement, 2016.
2. Bayer. Zepatier prescribing information, 2023.
3. IQVIA. Global HCV market analysis, 2023.
4. EvaluatePharma. Hepatitis C treatments market forecast, 2023-2028.
5. Gilead Sciences. Competitor product sales and market share data, 2022.